Login to Your Account



Global Biosimilar Pipeline Flowing with Promise

By Mari Serebrov
Washington Editor

Wednesday, November 27, 2013

While patents continue to clog the U.S. biosimilar pipeline, other countries are benefiting from an increasing flow of the discounted copies of complex biologics. Using a biosimilar pathway developed in 2012, India last week approved the first follow-on to pour from Mylan Inc.’s partnership with Indian drugmaker Biocon Ltd. – a biosimilar Herceptin (trastuzumab, Roche Group).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription